GPhA: Survey evidence FDA generics rule would confuse prescribers
This article was originally published in Scrip
Executive Summary
The Generic Pharmaceutical Association (GPhA) on 18 June argued the results of a new survey is evidence the FDA's proposal to permit generic drug makers to independently update their US product labeling with newly-acquired safety information before regulators review those changes would lead to confusion for prescribers and pharmacists.